The only mechanistically plausible entry point for Eniola in this roundup is the LCRF Research Grant, and it is a long-shot requiring deliberate reframing: her ODE/RK45 models and Bayesian MCMC framework operationalise a generalised 'consolidation threshold' for pharmacological resistance — a framework that, if explicitly extended to tyrosine-kinase inhibitor (TKI) resistance in NSCLC (where non-genomic, memory-consolidation-like adaptive resistance is poorly characterised), could be made lung-cancer adjacent. TOPOLOGIX's persistent-homology drug-protein interaction engine is also directly relevant to resistance-mechanism discovery. The strategic pitch would be: 'computational resistance modeller with a validated threshold-dynamics framework, seeking to apply it to TKI resistance in partnership with an LCRF-eligible lung cancer laboratory' — i.e., enter as a computational collaborator on a team application rather than as lead PI. However, she cannot apply solo: LCRF requires non-profit institutional affiliation, and ZYCO's status as a qualifying institution would need to be confirmed against their RFA language.